california inc pacb-
take-out ahead inflect point surpris thought result
invest summari maintain overweight rate pt share
yesterday nov cover announc agreement acquir
pacbio per share all-cash transact repres
premium prior close said along view pacbio
attract asset thought tie-up would year road think
pacbio verg inflect point approach excit product
launch compani histori potenti drive significantli higher
valuat said view overal posit wonder
saw pacbio potenti threat market share futur
 view anoth bidder possibl decis go leader
long-read sequenc valid long-read pacbio view
player sequenc market view viabl competitor may
attract pursu pacbio ahead launch million well chip
view like suitor roch cover roch
hostil take-over attempt prior partnership pacbio creat
 valuat de-risk execut million well chip expect
million well chip drive util would warrant higher
valuat view howev remov risk execut ad
global reach may bridg gap expect valuat level
today
give time regulatori approv transact expect
close give plenti time obtain necessari
regulatori approv view complement pacbio claim
short-read long-read technolog compet directli view
regulatori hurdl high risk even though pacbio share mani
custom obtain approv china may necessari could
top-lin miss pacbio report revenu y/i
factset consensu miss driven lower system
consum sale custom wait new product launch
lower consum rsii system expect weak continu
next two quarter lower revenu estim
respect also lower
ep estim
disclosur section may found page
exhibit comparison cantor estim
california inc million except per share current priorcurr priorp gross gross gener share novemb
base price target ev/sal multipl revenu estim
discount back wacc multipl repres premium averag
may year away profit capital-intens busi may
requir access capit build toward profit failur gener addit capit may
prevent compani reach profit
next gener sequenc market competit next gener sequenc
market grow rapid pace howev industri leader includ
cover market share market leader larg compani signific
financi resourc could make difficult smaller compani like compet smaller
compani also fight share
visibl busi may limit manag suspend revenu guidanc
highlight lack visibl quarterli cadenc busi instrument sale lumpi
natur therefor forecast futur busi may difficult recogn revenu
instrument placement instal also may difficult predict larg piec
capit equip may requir high level plan laboratori
academ govern fund environ could chang typic sell
instrument academ research institut lab fund govern grant fund
environ chang dramat less commit genom healthcar
gener may advers effect
california
million except per share data
cost good sold
interest expens incom
incom incom tax
compani document cantor fitzgerald research
found base menlo park ca pacif bioscienc california develop manufactur market next-
gener sequenc instrument consum relat servic compani singl molecul real-tim smrt platform
includ pacbio rs ii instrument sequel character offer high consensu accuraci long read length
compani product enabl de novo genom assembl finish genom order more- identifi annot deciph genom
structur full-length transcript analysi improv annot refer genom character altern splice isoform
find novel gene target sequenc more-comprehens character genet variat dna base modif identif
help character epigenet regul dna damag compani market portfolio integr system consum
analysi tool wide rang custom includ genom research center academ institut govern laboratori hospit
refer laboratori well pharmaceut biotechnolog agbio commerci molecular diagnost compani
price close
